18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer

Journal of Nuclear Medicine

Volumn 47, Issue 3, 2006, Pages 492-501

  Zhang, Xianzhong ^a   Cai, Weibo ^a   Cao, Feng ^a   Schreibmann, Eduard ^a   Wu, Yun ^a   Wu, Joseph C ^a   Xing, Lei ^a   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F bombesin; GRP receptor; microCT; microPET; Prostate cancer

Indexed keywords

AMINOCAPROIC ACID DERIVATIVE; BOMBESIN; FLUORINE 18; GASTRIN RELEASING PEPTIDE RECEPTOR; LYSINE; TRACER; BOMBESIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EFFUSION; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RADIOASSAY; RECEPTOR BINDING; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; DRUG DELIVERY SYSTEM; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FLUORINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33645958934     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. di Sant'Agnese PA. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects. Urology. 1998;51:121-124.
2. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47:147-155.
3. Chung DH, Evers BM, Beauchamp RD, et al. Bombesin stimulates growth of human gastrinoma. Surgery. 1992;112:1059-1065.
4. Glover SC, Tretiakova MS, Carroll RE, Benya RV. Increased frequency of gastrin-releasing peptide receptor gene mutations during colon-adenocarcinoma progression. Mol Carcinog. 2003;37:5-15.
5. Battey J, Wada E, Corjay M, et al. Molecular genetic analysis of two distinct receptors for mammalian bombesin-like peptides. J Natl Cancer Inst Monogr. 1992;13:141-144.
6. Scheffel U, Pomper MG. PET imaging of GRP receptor expression in prostate cancer. J Nucl Med. 2004;45:1277-1278.
7. Matusiak D, Glover S, Nathaniel R, Matkowskyj K, Yang J, Benya RV. Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. Am J Physiol Gastrointest Liver Physiol. 2005;288:G718-G728.
8. Fathi Z, Corjay MH, Shapira H, et al. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem. 1993;268:5979-5984.
9. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res. 1994;54:169-174.
10. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005;46(suppl 1):67S-75S.
11. Maina T, Nock BA, Zhang H, et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med. 2005;46:823-830.
12. Varvarigou A, Bouziotis P, Zikos C, Scopinaro F, De Vincentis G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm. 2004;19:219-229.
13. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722-1727.
14. 13-BN1). Cancer Biother Radiopharm. 2004;19:245-252.
15. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-6715.
16. 2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res. 2003;23:63-70.
17. 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-763.
18. 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother Radiopharm. 2004;19:25-34.
19. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-1397.
20. 68Ga-labeled bombesin(6-14) analog. J Nucl Med. 2005;46:691-699.
21. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001;28:929-938.
22. 18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. Bioconjug Chem. 1994;5:352-356.
23. 18F-Labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
24. 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
25. 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging. 2004;31:1081-1089.
26. 18F-labeled dimeric RGD peptide. Mol Imaging. 2004;3:96-104.
27. 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41-49.
28. Hillman GG, Wang Y, Kucuk O, et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther. 2004;3:1271-1279.
29. Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med. 2001;42:808-817.
30. Schreibmann E, Xing L. Narrow band deformable registration of prostate magnetic resonance imaging, magnetic resonance spectroscopic imaging, and computed tomography studies. Int J Radiat Oncol Biol Phys. 2005;62:595-605.
31. Benedetti E, Morelli G, Accardo A, Mansi R, Tesauro D, Aloj L. Criteria for the design and biological characterization of radiolabeled peptide-based pharmaceuticals. BioDrugs. 2004;18:279-295.
32. 99mTc: a preclinical study. J Med Chem. 2005;48:100-110.
33. 3 integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:6146-6151.
34. 111In-DTPA] octreotide. J Nucl Med. 2004;45:1168-1171.
35. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
36. 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
37. 111In- labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med. 2003;44:823-831.
38. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging. 1997;16:187-198.
39. du Bois d'Aische A, Craene MD, Geets X, Gregoire V, Macq B, Warfield SK. Efficient multi-modal dense field non-rigid registration: alignment of histological and section images. Med Image Anal. 2005;9:538-546.
40. Thomas CT, Meyer CR, Koeppe RA, et al. A positron-emitting internal marker for identification of normal tissue by positron emission tomography: phantom studies and validation in patients. Mol Imaging Biol. 2003;5:79-85.